MANAGEMENT AND TEAM

Jordi Naval

CEO

Jordi is an experienced biotech CEO (+20 years), with a track record in early-stage development. Jordi has raised more than 80 M in private and public funding for 5 biotechs, among them AELIX Therapeutics.

Peter Johannes Holst

CSO

Dr. Holst is the founder of InProTher and has a long-standing experience within immunology and has made pivotal discoveries in these fields. He has taken virus-vectored vaccines further by developing the first clinically effective genetic adjuvants. Peter Holst’s prior inventions are in clinical trials and licensed to GSK.

Nicolaj Højer Nielsen

CFO

Nicolaj Højer Nielsen is a serial entrepreneur with +15 years of experience in bringing innovative products to the market, building up management teams and securing project funding. His prior career includes positions at Foss and ALK-Abello and assignments for leading biotech companies including Bavarian Nordic.

Anne-Marie Andersson

CTO & DIRECTOR OF CMC

Dr. Andersson developed the Virus-Like vaccine platform in the research laboratory of Peter Holst. Designed adenoviral vectors against retroviruses and produced poxvirus vectors. She returns from Oxford University and is responsible for the continuous development of our vaccine platform and process development.

Mathias Kroll

CBO

Dr. Kroll has 20 years of international experience in research and business development in the pharmaceutical sector, and a track record in licensing, M&A and partnerships and extensive experience from the vaccine industry. His career includes positions at Bavarian Nordic (VP Head of Global Business Development) and GSK Biologicals (Senior Director).

Karen Nørgaard Nielsen

DIRECTOR CLINICAL DEVELOPMENT

Dr. Nørgaard was trained in adenovirus vaccine development before becoming a Novo Nordisk clinical trial manager. Dr. Nørgaard then did her PhD in genetic models of immunometabolism before joining InProTher to oversee our pre-clinical program.

Emeline Raggonaud

DIRECTOR PRECLINICAL R&D

Dr. Ragonnaud joined InProTher in June 2020 after leaving the National Institutes of Health (NIH) in Baltimore, US. At NIH, Dr. Ragonnaud’s primary focus was the role of B cells in cancer progression. Before her 3-year postdoctoral fellowship at NIH, she did her PhD in Peter Holst’s research group.

Valdemar Stage

DIRECTOR OF FINANCE

Valdemar Stage holds a M.Sc. Finance and Accounting from CBS. Former management consultant in the medtech industry. Valdemar has been involved with multiple biotech startups securing financing, most notably Adcendo’s 51M EUR Series A. He has worked with listed biotech companies helping to prepare for a NASDAQ main market listing.